Visão geral da empresa
Semler Scientific, Inc. operates within the healthcare sector, specifically serving the medical devices industry by providing technology solutions designed to enhance the clinical effectiveness and operational efficiency of healthcare providers in the United States. The company's product portfolio includes specialized equipment such as the QuantaFlo, a four-minute in-office blood flow test that facilitates the use of blood flow measurements in clinical settings. At a market capitalization of $311.11M, the company is classified as a small-cap entity with an annualized revenue of $36.96M and an employee base of 79 individuals. These valuation and revenue figures indicate that Semler Scientific functions as a niche player rather than a dominant market leader, operating with a relatively lean workforce to generate its current financial results.
Saúde financeira
The company reported a revenue of $36.96M over the trailing twelve months, yet posted a net income of $48.34M, creating a significant discrepancy that suggests non-operating income sources are heavily influencing the bottom line. This divergence between revenue and net income is further evidenced by an EBITDA of -$5,020,000, highlighting a substantial gap between operational profitability and reported earnings before interest, taxes, and amortization. Free cash flow stands at -$33,146,500, indicating that the company is currently burning cash, which limits its immediate financial flexibility for capital expenditures or acquisitions without external financing. Margin analysis reveals a gross margin of 90.8%, demonstrating exceptional efficiency in production and cost of goods sold, contrasted sharply by an operating margin of -72.0% that points to high overhead costs or significant restructuring expenses. The profit margin of 130.8% confirms that the company is generating net income exceeding its total revenue, likely due to one-time gains or other comprehensive income items not captured in operating metrics. On the balance sheet, the company holds $10.18M in cash against $116.42M in total debt, resulting in a debt-to-equity ratio of 25.32, which characterizes the capital structure as highly leveraged and potentially vulnerable to interest rate fluctuations. Liquidity is supported by a current ratio of 1.97, suggesting the firm possesses nearly twice the current assets required to cover its short-term liabilities, providing a buffer against immediate obligations. Return on equity is reported at 17.7%, while return on assets is -1.0%, illustrating a scenario where management is generating returns for shareholders through leverage despite the company's assets collectively destroying value on an absolute basis.
Avaliação de valorização
Valuation metrics present a complex picture, with a trailing P/E ratio of 3.93 juxtaposed against a forward P/E of 254.43, implying that the market expects a dramatic turnaround in earnings that is not yet reflected in current trailing figures. The price-to-book ratio of 0.67 indicates that the stock is trading at a discount to its book value, suggesting the market may be pricing in significant operational risks or asset quality concerns. Alternative valuation multiples such as the price-to-sales ratio of 8.42 and the EV/EBITDA of -82.56 further complicate the assessment, as the negative EV/EBITDA reflects the company's current inability to generate positive operating cash flows relative to its enterprise value. Price momentum is contained within a 52-week range between $14.88 and $54.40, meaning the current share price sits within this historical volatility band, trading significantly below the recent high of $54.40. The beta of 1.32 indicates that the stock's price volatility is 32% higher than the broader market, making it a high-risk instrument that is likely to experience amplified swings during periods of market stress.
Growth & Income
Growth dynamics show a revenue decline of -44.6% year-over-year, while earnings growth stands at 49.3%, indicating that earnings are expanding at a much faster rate than revenue due to the aforementioned non-operating income distortions. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all earnings are retained within the business rather than distributed to shareholders. This reinvestment strategy is typical for companies in turnaround phases or those prioritizing balance sheet repair over income generation for investors. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, relying entirely on potential future operational improvements to restore cash flow and profitability.